Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer
Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients With Cachexia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610-0219
- University of Florida Clinical Research Center (CRC)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 21 year or older
- medical diagnosis of gastrointestinal cancer (for example, gastric, biliary, or colorectal)
- experienced weight loss of at least 5% over the last 6 months
- ability to communicate in English
- ability to follow the research protocol
Exclusion Criteria:
- plan to have surgical procedures at the time of recruitment
- receive radiation therapy alone or in addition to chemotherapy during the study period
- undergo surgery during the study or in the months prior to the study
- no plan to have chemotherapy after the surgery
- any comorbidities that may affect the interpretation of study findings
- open burn sites or infected wounds
- esophageal cancer or pancreatic cancer
- life expectancy of less than 6 months as assessed by attending physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cachexia Acupuncture-A
Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period. Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture |
Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
Other Names:
|
|
Sham Comparator: General Acupuncture-B
General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted. Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture |
Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage weight change over 8 weeks between two arms
Time Frame: up to 8 weeks
|
Weight will be measured each visit (pounds).
|
up to 8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appetite change between two arms
Time Frame: up to 8 weeks
|
Three different short survey forms will be used to measure appetite change.
Visual analogue scale (0 indicates no appetite and 10 is the best appetite).
Simplified Nutritional Appetite Questionnaire score (min-max: 4-20 and the higher the better appetite) Patient Generated Subjective Global Assessment: 0-1, no intervention is needed.
9 or higher score indicates critical intervention.
|
up to 8 weeks
|
|
physical functioning
Time Frame: up to 8 weeks
|
survey form (min-max: 0-100, increment by 10%- 100% indicates full functioning).
|
up to 8 weeks
|
|
body composition
Time Frame: up to 8 weeks
|
Small, non-invasive device (bioelectrical impedance analysis) like a miniature version of EKG will measure changes in body composition (numeric scale).
|
up to 8 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life between two arms
Time Frame: up to 8 weeks
|
Survey format includes the 27 items (5 points scale: 0 means 'not at all' and 4 means 'very much") .
|
up to 8 weeks
|
|
biomarkers
Time Frame: weeks 1, 4 and 8 (three measurements)
|
Small amounts of blood will be drawn.
|
weeks 1, 4 and 8 (three measurements)
|
|
symptom experience
Time Frame: up to 8 weeks
|
Survey format: 13 areas related to the symptom experience and patient's concerns will be assessed (4 points scale; 0 means 'not at all' and 3 means 'very much').
|
up to 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Saunjoo Yoon, PhD, University of Florida
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB201400340
- OCR14647 (Other Identifier: University of Florida)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasm of Gastrointestinal Tract
-
NCT02575898CompletedPrimary Malignant Neoplasm of Lung | Primary Malignant Neoplasm of Gastrointestinal Tract
-
NCT01563991CompletedBenign Neoplasm of Intestinal Tract | Primary Malignant Neoplasm of Intestinal Tract | Secondary Malignant Neoplasm of Intestinal Tract
-
NCT01639911CompletedMelanoma | Head and Neck Neoplasms | Malignant Neoplasm of Breast | Malignant Neoplasm of Thorax | CNS Malignancy | Malignant Neoplasm of Gastrointestinal Tract | Genitourinary Neoplasms Malignancy and Gender Unspecified
-
NCT02757222CompletedMalignant Neoplasm of Oropharynx Stage III | Malignant Neoplasm of Larynx Stage III | Malignant Neoplasm of Hypopharynx Stage III | Malignant Neoplasm of Oropharynx Stage IVa | Malignant Neoplasm of Oropharynx Stage IVb | Malignant Neoplasm of Larynx Stage IV | Malignant Neoplasm of Hypopharynx Stage IVa | Malignant Neoplasm of Hypopharynx Stage IVb
-
NCT01360411CompletedSecondary Malignant Neoplasm of Lymph Node | Disorder of Upper Gastrointestinal Tract | Pancreatic Nodule | Secondary and Unspecified Malignant Neoplasm of Retroperitoneal Lymph Nodes
-
NCT02845908CompletedMalignant Neoplasm of Stomach Stage IV
-
NCT02697838UnknownClinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric CancerMalignant Neoplasm of Stomach Stage II
-
NCT04975256TerminatedMetastatic Cancer | Advanced Cancer | Malignant Neoplasm of Colon | Malignant Neoplasm of Lung | Malignant Neoplastic Disease
-
NCT02205047CompletedMalignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
-
NCT01861691UnknownMalignant Neoplasm of Transverse Colon | Malignant Neoplasm of Descending Colon
Clinical Trials on Cachexia Acupuncture-A (Peace Classic Needles® )
-
NCT00913354Completed
-
NCT02890810CompletedBack Pain | Chronic Low Back Pain
-
NCT01881932Terminated
-
NCT03391986CompletedAcupuncture | Pain Acute
-
NCT05507736CompletedSolid Tumor | Pediatric Cancer
-
NCT01316614CompletedBiopsy, Fine-Needle | Endosonography | Biopsy, Fine-Needle/Methods
-
NCT01883908TerminatedMucositis | Oropharyngeal Cancer
-
NCT02707705CompletedAnxiety Reduction, Elective Cesarean Section
-
NCT04881942Completed